Patent expiry creates $5bn opportunity for Indian pharma

According to the CareEdge Ratings report, this patent expiry cycle is expected to create a market opportunity exceeding $30-40 billion over five years, of which, Indian companies are expected to capture nearly $3-5 billion. The report identifies Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories as companies that could potentially benefit from this available opportunity. As noted by CareEdge Ratings, "After accounting for significant price erosion, this is expected to create a market opportunity exceeding $30-40 billion over five years, of which, Indian companies are expected to capture nearly $3-5 billion."

According to CareEdge Ratings, over 60 per cent of drugs losing exclusivity are large-molecule biologics, marking a structural shift from earlier patent cycles that were dominated by small-molecule drugs. As explained by Pritesh Rathi, Associate Director at CareEdge Ratings, "Unlike previous patent cliffs that were largely driven by small-molecule drugs, this cycle is increasingly focused on large-molecule biologics, which are inherently more complex to develop, manufacture, and replicate." Large molecules are complex proteins produced in living cells, making biosimilars difficult to produce and scale compared to small molecules, which are simple drugs made by chemical synthesis.

As reported by CareEdge Ratings, a significant share of these drugs are chronic therapies, where early market entry becomes critical as prescribing practices and patient stickiness are established up front—making speed-to-market more important than pure cost advantage. The report emphasizes that Indian companies are well-positioned to capitalize on this opportunity due to their proven cost-efficient generic manufacturing capabilities and favorable patent framework. This represents a significant shift from previous patent cycles where small-molecule drugs dominated the generic market entry.